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BACKGROUND: Carnitine plays essential roles in energy production, oxidative stress and glucose metabolism. This
study was planned to determine serum total L-carnitine levels in non-obese women with polycystic ovary syndrome
(PCOS). METHODS: There were 27 non-obese women with PCOS and 30 healthy, age- and body mass index
(BMI) matched controls were evaluated in this controlled clinical study. Serum lipid sub-fractions, fasting glucose,
insulin and other hormones (gonadotrophins, androgens) and total L-carnitine levels were measured. Homeostasis
model assessment (HOMA-IR) was used to estimate insulin resistance. RESULTS: The women with PCOS had signifi-
cantly higher serum dehydroepiandrosterone sulfate, total testosterone, free androgen index (FAI), luteinizing
hormone (LH), low-density lipoprotein (LDL) cholesterol, non-high density lipoprotein (HDL) cholesterol, fasting
insulin levels and HOMA-IR measurement and LH/FSH ratios than healthy women. However, total L-carnitine
and sex hormone-binding globulin (SHBG) levels were significantly lower in women with PCOS. L-Carnitine level
was negatively correlated with FAI, but positively correlated with SHBG. Multiple regression analysis revealed
that SHBG was a strong predictor of serum total L-carnitine level. CONCLUSIONS: Decreased total L-carnitine
levels may be associated with hyperandrogenism and/or insulin resistance in non-obese women with PCOS. Long-
term studies are needed to evaluate carnitine metabolism in PCOS, especially with regard to the molecular basis.
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Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous endo-
crine disorder, affecting 7% of reproductive age women
(Asuncion et al., 2000), and is characterized by chronic anovu-
lation, hyperandrogenism and disordered gonadotropin
secretion (Dunaif, 1997). Its clinical and biochemical manifes-
tations may include oligo-amenorrhea, obesity, enlarged cystic
ovaries, elevated luteinizing hormone (LH), signs of androgen
overproduction and reduced fertility. Insulin resistance plays
pivotal roles in the pathogenesis of PCOS (Arslanian et al.,
2001), even though the mechanisms underlying PCOS are
not completely understood. The presence of hyperinsulinemia
in patients with PCOS, independent of obesity, was previously
confirmed (Dunaif et al., 1989). Hyperinsulinemia occurs as a
result of insulin resistance and accelerates ovarian androgen
overproduction (Dunaif et al., 1992). Hyperinsulinemia may
also contribute to the development of diabetes and dyslipide-
mia in PCOS patients (Dunaif, 1997). We have previously
shown that there is increased oxidative stress and decreased
antioxidant capacity in patients with PCOS (Fenkci et al.,
2003).
Carnitine plays an essential role in fatty acid metabolism by
facilitating the transport of long-chain free fatty acids into the
mitochondrial matrix, making them available for b-oxidation,
which is the most efficient metabolic pathway for energy pro-
duction (Borum, 1980). Carnitine also plays a key role in
glucose metabolism and in fuel-sensing, because it behaves
as a shuttle for acetyl groups from inside to outside the mito-
chondrial membrane. Accumulation of acyl-CoA and acetyl-
CoA compounds inside the mitochondria is implicated in the
pathogenesis of lipid-induced insulin resistance (Mingrone,
2004; Power et al., 2007). Carnitine has also an antioxidant
capacity and improves oxidative stress (Mister et al., 2002;
Gómez-Amores et al., 2006).
This study was planned to determine serum total L-carnitine
levels in non-obese women with PCOS. To the best of our
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knowledge, we present the first study concerning serum total
carnitine levels in PCOS.
Materials and Methods
Subjects
There were 27 non-obese patients with PCOS (study group) and 30
healthy women (control group) included in the study. The patients’
ages ranged from 16 to 37 years. The diagnosis of PCOS was based
on the recommendations of Rotterdam consensus conference on
PCOS by at least two of the following three features: (i) oligo- or ano-
vulation, (ii) clinical and/or biochemical signs of hyperandrogenism
and (iii) polycystic ovaries (The Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2004). All subjects
in study group had clinical hyperandrogenism [presence of acne,
Ferriman–Gallwey score of 8] (Ferriman and Gallwey, 1961),
oligomenorrhea (fewer than six menstrual periods in the preceding
year) and the presence of 12 or more subcapsular follicles in each
ovary measuring 2–9 mm in diameter by transvaginal ultrasound
examination. Exclusion criteria comprised infectious diseases,
hypertension, family history of cardiovascular disease, chronic liver
diseases, endocrinopathies including diabetes, Cushing’s syndrome,
androgen secreting tumors, non-classical 21-hydroxylase deficiency,
thyroid dysfunction, hyperprolactinemia, smoking, alcohol consump-
tion and use of all medications known to alter sex hormones, lipo-
protein, carnitine metabolism, or insulin secretion or action.
The women in the control group had regular menstrual cycles that
were defined as cyclic uterine bleedings with duration of 4–5 days
and a frequency of 25–34 days. The healthy state of control subjects
was determined by medical history, physical and pelvic examination,
and whole blood chemistry. None of the 30 healthy women in the
control group met any exclusion criteria mentioned above. This
work was approved by the local medical ethics committee and all
participants gave informed consent before the onset of study.
Biochemical analysis
Venous blood samples were drawn from all participants after fasting
for 12 h on the study day (on cycle days 3–5 after spontaneous or
progesterone-induced menses in the PCOS and control groups).
Samples were collected in serum separator tubes, allowed to clot for
30 min, centrifuged for 15 min at 2000  g at room temperature and
aliquoted into polypropylene tubes. All biochemical measurements
were performed on same day except L-carnitine. For total L-carnitine
measurements, the aliquoted samples were stored in 2208C until ana-
lysed. Biochemical measurements were done by using commercial
kits. The sera were assayed for fasting glucose (F.Glc), triglyceride
(TG), total cholesterol (TC), HDL cholesterol, insulin, dehydroepian-
drosterone sulfate (DHEA-S), sex hormone-binding globulin (SHBG),
follicle-stimulating hormone (FSH), LH, total testosterone and total
L-carnitine. Serum glucose (hexokinase), TC (CHOD-PAP) and TG
(GPO-PAP) concentrations were measured using standard enzymatic
methods (Roche Diagnostics, IN, USA) with a fully automated analy-
ser (Roche Modular PE, Roche Diagnostics). HDL-cholesterol con-
centrations were measured without precipitation by using liquid
selective detergent homogeneous technique (Roche HDL-C plus 2nd
generation, Roche Diagnostics). LDL levels were calculated by
using Friedewald’s formula. Non-HDL cholesterol levels were com-
puted by the formula: non-HDL ¼ TC 2 HDL. Fasting insulin,
FSH, LH and total testosterone concentrations were measured using
electrochemiluminescence’s immunoassay (Roche Diagnostics) with
a fully automated analyser (Roche Modular PE, Roche Diagnostics).
SHBG, DHEA-S immunometric assays were performed using a
solid phase competitive chemiluminescence’s immunoassay (IMMU-
LITE 2000, DPC Biosystems, CA, USA).
FAI was defined here as 100 times the molar ratio of total testoster-
one to SHBG [FAI ¼ 100  total testosterone (in nmol/l)/SHBG (in
nmol/l)].
Insulin resistance was calculated by using homeostasis model
assessment (HOMA-IR) score that employs the formula: fasting
insulin concentration (mIU/l)  glucose (mmol/l)/22.5 (Matthews
et al., 1985).
For total L-carnitine measurements, all samples of the subjects were
assessed during a single assay run. The measurements were performed
using a commercial kit (Roche Diagnostics GmbH, Penzberg,
Germany) according to the instructions of the manufacturer. The
test was based on the measurement of the amount of NADH consumed
during the reaction. The test was linear in the range of 5.6–112 mmol/
l of L-carnitine. Samples with L-carnitine levels above the linearity
range were diluted according to the instructions of the manufacturer.
For biochemical measurements, the within-run CV values were
ranging between 0.7 and 2.1%, and the between-run CV values were
ranging between 1.2 and 2.6%.
Anthropometric measurements
All anthropometric measurements were done by the same physician on
the day that the blood specimen was taken. Waist circumference (c.m.)
was taken with a tape measure as the point midway between the costal
margin and iliac crest in the mid-axillary line with the subject standing
and breathing normally and hip c.m. was measured at the widest point
around greater trochanter. Body mass index (BMI) (Body weight
(kg)/height m2) and waist-to-hip ratio (WHR) were computed.
Statistical analysis
At the beginning of the study, all study participants were matched for
age and BMI. The healthy controls were defined as age- and BMI-
matched with subjects when the differences in age and BMI were
less than 2 years and less than 1 kg/m2, respectively. Since many vari-
ables had a Gaussian distribution with no significant skewness, statisti-
cal analysis was performed with a parametric test: Student’s t-test.
Correlations between variables were calculated with Pearson’s
correlation coefficient. Stepwise multiple regression analysis introdu-
cing the serum total L-carnitine level as a dependent variable and
androgens, SHBG and HOMA-IR as independent variables
(r ¼ 0.610, r2 ¼ 0.373, Adjusted r2 ¼ 0.361, Durbin–Watson ¼
2.266, F ¼ 32.663, P ¼ 0.0001) was also conducted. After each
addition of a new independent variable to the equation, all previously
entered independent variables were checked to see whether they
maintained their level of significance. Previously entered independent
variables were retained in the regression equation only if their removal
would have caused a significant reduction in r2. The data are expressed
as means+SE. Statistical significance was set at
P , 0.05. Data were analysed with the SPSS (Statistical Package
for the Social Science, version 11.0).
Results
There were no statistically significant differences in the waist
measurements, WHR and serum FSH, F.Glc, TC and TG and
HDL levels between the groups. Ferriman–Gallwey score,
serum LH, total testosterone, DHEA-S, fasting insulin, LDL
levels and LH/FSH ratio, FAI and HOMA-IR were signifi-
cantly higher in patients with PCOS compared with controls
(for each parameter P , 0.05). However, the women with
PCOS had significantly lower serum SHBG and total
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L-carnitine levels than did healthy subjects (for each parameter;
P , 0.05) (Tables I and II).
BMI was positively associated with waist measurement (r ¼
0.40, P ¼ 0.002). Serum total L-carnitine level was negatively
correlated with FAI (r ¼ 20.32, P ¼ 0.016), but positively
with SHBG (r ¼ 0.61, P ¼ 0.0001). FAI was positively associ-
ated with LH (r ¼ 0.62, P ¼ 0.0001), LH/FSH ratio (r ¼ 0.50,
P ¼ 0.0001), total testosterone (r ¼ 0.70, P ¼ 0.0001)
DHEA-S (r ¼ 0.31, P ¼ 0.017), LDL (r ¼ 0.28, P ¼ 0.033),
non-HDL (r ¼ 0.34, P ¼ 0.011), fasting insulin (r ¼ 0.53,
P ¼ 0.0001), HOMA-IR (r ¼ 0.51, P ¼ 0.0001), and nega-
tively associated with SHBG (r ¼ 20.61, P ¼ 0.0001).
SHBG was negatively correlated with LH/FSH ratio (r ¼
0.50, P ¼ 0.0001), HOMA-IR (r ¼ 20.36, P ¼ 0.005) and
fasting insulin (r ¼ 20.40, P ¼ 0.003). On the other hand,
there was a positive relationship between HOMA-IR and TG
(r ¼ 0.42, P ¼ 0.001). As seen above, the degrees of relation-
ships between many variables were statistically significant yet
small, except the association between FAI and LH which was
strong. Moreover, the correlation between serum total
L-carnitine level and SHBG was strong. Stepwise multiple
regression analysis introducing the serum total L-carnitine
level as a dependent variable and androgens, SHBG and
HOMA-IR as independent variables revealed that SHBG was
a strong predictor of serum total L-carnitine level (b ¼ 0.610,
P ¼ 0.0001) (Table III).
Discussion
Carnitine is a trimethylamine molecule, which plays an import-
ant role in cell energy metabolism. Carnitine is synthesized
primarily in the liver and kidney from lysine and methionine
(Bremer, 1983), but additional intestinal resorption is necess-
ary (Sealey and Laragh, 1975). Carnitine facilitates energy
availability, and is particularly vital for those tissues with
high energy requirements such as cardiac and skeletal
muscles. These tissues are the major storage sites of carnitine.
Carnitine mediates the transport of activated acyl residues via
the carnitine palmitoyl transferase system into mitochondria
for b-oxidation (Bremer, 1983; Sealey, 1991). Carnitine also
acts as a carrier of acetyl groups from mitochondria to the
cytosol (Lysiak et al., 1988; Broderick et al., 1992), so that it
maintains sufficient amounts of free CoA for mitochondrial
function and protects mitochondria by reducing accumulation
of long-chain acylcarnitine in the mitochondrial space. Long-
chain acylcarnitine has a detergent effect on the mitochondrial
membrane. The myocardium utilizes both glucose and fatty
acids for energy metabolism. In the current study, we found
decreased levels of total L-carnitine in non-obese women
with PCOS. It may therefore be assumed that the energy
needed for cardiac contraction is not sufficiently supplied in
subjects with PCOS, since decreased levels of carnitine may
limit the availability of fatty acids in the mitochondria to
generate ATP.
The carnitine system is important in determining body com-
position, because it plays a critical role in insulin regulation of
fat and glucose metabolic rate in skeletal muscle (Reda et al.,
2003). The mechanism of carnitine action includes an increase
in glucose metabolism via stimulating glucose disposal and
oxidation (De Gaetano et al., 1999; Sethi et al., 1999). Also
carnitine may improve insulin sensitivity in insulin resistance
(Mingrone et al., 1999). On the other hand, above a threshold
level, hyperinsulinemia causes carnitine accumulation in
muscle cells via insulin-mediated stimulation of muscle carni-
tine transport leading to a decrease in total serum carnitine
Table I. Clinical features and steroid levels for the healthy controls and the
women with PCOS.





Age (years) 25.0+1.42 26.1+0.6 0.46
BMI (kg/m2) 24.7+0.6 23.5+0.6 0.15
Waist (c.m.) 80.4+0.9 79.0+1.3 0.40
Waist/hip ratio 0.78+0.01 0.79+0.01 0.35
FSH (mIU/ml) 6.70+0.40 5.9+0.4 0.22
LH (mIU/ml) 14.7+1.0 6.2+0.7 0.0001a




SHBG (nmol/l) 21.8+1.6 75.1+7.9 0.0001a
FAI 11.3+0.9 2.2+0.2 0.0001a
DHEA-S (mmol/l) 5.1+0.4 3.8+0.4 0.02 a
aP , 0.05 statistically significant. BMI, body Mass Index; FSH,
follicle-stimulating hormone; LH, luteinizing hormone; FAI, free androgen
index; SHBG, sex hormone-binding globulin; DHEA-S,
dehydroepiandrosterone sulfate.
Table III. Stepwise multiple regression analysis with serum L-carnitine level
as the dependent variable.
b P
Total testosterone (nmol/l) 0.033 0.766
SHBG (nmol/l) 0.610 0.0001a
FAI 0.087 0.522
DHEA-S (mmol/l) 0.101 0.361
HOMA-IR 0.056 0.630
aP , 0.05 statistically significant. SHBG, sex hormone-binding globulin;
FAI, free androgen index; DHEA-S, dehydroepiandrosterone sulfate;
HOMA-IR, homeostasis model assessment.
Table II. Metabolic characteristics and total L-carnitine levels for the
healthy controls and the women with PCOS.


















HDL (mmol/l) 1.3+0.1 1.5+0.1 0.19
LDL (mmol/l) 3.2+0.2 2.5+0.1 0.009a
Non-HDL (mmol/l) 3.8+0.2 3.1+0.2 0.02a
Carnitine (mmol/l) 40.5+5.7 91.1+15.2 0.004a
aP , 0.05 statistically significant. HOMA-IR, homeostasis model assessment;
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levels (Stephens et al., 2007). Independent of obesity, the
presence of hyperinsulinemia in PCOS was confirmed by the
outcomes of this study. We found an obviously higher level
of fasting insulin and HOMA-IR in subjects with PCOS
than in healthy controls, although BMI was in normal range
in each group. Despite low levels of serum total L-carnitine
in patients with PCOS, there were not any significant
correlation between serum total L-carnitine levels and insulin
resistance in this study. The requirement of a threshold level
for an insulin effect on the carnitine level may have obscured
a direct correlation.
Dyslipidemia is frequently accompanied by decreased HDL,
and increased TC, LDL, TG levels and can be observed in
insulin resistance conditions (DeFronzo and Ferrannini,
1991). It has been shown that carnitine has a hypotriglyceri-
demic effect (Gómez-Amores et al., 2006). Moreover, carni-
tine supplementation may relieve lipid overload (Power
et al., 2007). We did not observe any relationship between
serum total carnitine level and lipid fractions. But significantly
elevated LDL and non-HDL levels in subjects with PCOS were
found in this study. TC and TG levels were slightly higher,
whereas the HDL level was lower in patients with PCOS;
however, there were no significant differences in these lipid
fractions between both groups possibly due to the selection
of subjects who had normal BMI.
Oxidative stress is one of the major reasons of molecular
damage to cellular structures and is implicated in the pathogen-
esis of the atherosclerosis, diabetes mellitus or
ischemia-reperfusion injury (Betteridge, 2000). Carnitine
improves repair mechanisms for oxidative stress-induced
damage to membrane phospholipids (Sethi et al., 1999), and
also maintains general antioxidant status (Savitha and Panneer-
selvam, 2006). It protects cells from reactive oxygen species
(Mister et al., 2002; Gómez-Amores et al., 2006) by acting
as a free radical scavenger (Vanella et al., 2000; Arockia
Rani and Panneerselvam, 2001). Also carnitine reduces trans-
cardiac endothelin concentrations (Lango et al., 2005), and
enhances endothelium-dependent relaxations (Mauriello
et al., 1996; Cipolla et al., 1999), therefore it partially improves
vascular reactivity (Irat et al., 2003). Carnitine diminishes the
ischemia-induced apoptosis as well (Vescovo et al., 2002;
Ferrari et al., 2004). Previously, we reported increased oxi-
dative stress and decreased antioxidant capacity in patients
with PCOS (Fenkci et al., 2003). These observations suggest
that low levels of antioxidant carnitine may further contribute
to the harmful effects of increased oxidative stress in non-obese
women with PCOS.
Serum carnitine levels may be influenced by androgens and
estrogens (Borum, 1980). Total and free carnitine levels are
lower in women than men (Chiu et al., 1999; Opalka et al.,
2001), because estrogen reduces serum free carnitine levels
(Takiyama and Matsumoto, 1998). In addition, androgens
may induce an increase in serum carnitine concentrations
(Borum, 1980). It was observed that carnitine levels were
correlated with DHEA-S levels and DHEA-S could modulate
carnitine levels (Chiu et al., 1999). In our investigation, we
found increased clinical and biochemical signs of hyperandro-
genism, but there was decreased serum total L-carnitine level in
women with PCOS. Also the serum total L-carnitine level was
negatively correlated with FAI, but positively correlated with
SHBG. On the other hand, HOMA-IR was inversely correlated
with SHBG, but positively correlated with FAI. Multiple
regression analysis revealed that only SHBG was a strong pre-
dictor of serum the total L-carnitine level. These outcomes were
in conflict with the observations mentioned above. We assume
that both androgen excess and insulin resistance, being inver-
sely related to SHBG, may have an effect in the same direction,
that is, they may both influence carnitine levels negatively.
In conclusion, the outcomes of this study suggest that
decreased serum total L-carnitine levels may be related with
hyperandrogenism and/or insulin resistance in non-obese
women with PCOS. In terms of carnitine activity, insulin resist-
ance, oxidative stress and dyslipidemia, long-term studies are
needed in PCOS, especially with regard to the molecular
basis of the interactions.
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